Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group), a leading Saudi pharmaceuticals company announced today a partnership with Leosons Overseas Corporation, a consumer health company based in the United States through an Exclusive Licensing and Distribution agreement to manufacture and commercialize Leosons products in the MENA region.
Through this agreement, Tabuk will have the right to register, manufacture, and commercialize a range of 14 brands in several countries in the MENA region. This include several products including Jointflex®, NICE®, Leolyte®, Fiberall®, CHOOZ®, Gas-Aid®, Leona’s Vitamins®, and Clear Mist®.
This agreement grants Tabuk an immediate take over for Leosons existing business in more than 10 markets with future expansion plans to include new markets and products, and supported by Tabuk’s strong presence in the MENA region to provide consumers with solutions that will enhance health and wellbeing.
Mohammed AlHaqbani , President of Astra Industrial Group commented: “ It has been an exciting year for Tabuk and partnering with a key player in consumer health as Leosons demonstrates the importance of such segment which continues to grow at a blistering pace. We aim to continue and build on the existing business of Leosons in the region especially with our objective to localize key products at Tabuk sites”
Wisam Alkhatib , Vice President of Strategy and Business Development at Tabuk Pharmaceuticalscommented: “At Tabuk Pharmaceuticals, we are excited to partner with Leosons, one of the leading players in the consumer health sector. We are confident that this agreement will strengthen our market leading position and support our strategic objective to further expand our business in KSA and the MENA region. We consider this partnership a step forward towards augmenting our plans for long-term growth and strengthening Tabuk’s over the counter business with direct contact with patients”.
John L. Ohanian , President of Leosons commented : “Leosons Overseas has demonstrated a sustained commitment to expansion where the business is widespread over 6 continents with 200 products sold to 30 plus countries yet our focus has remained the MENA region, therefore we believe our partnership with Tabuk Pharmaceuticals is transformational especially in Saudi Arabia.”
Leo Ohanian , Managing Director of Leosons, commented: “We are very pleased to establish a partnership with Tabuk Pharmaceuticals for the MENA markets. As the largest private Saudi Pharmaceutical company, Tabuk is an ideal partner to commercialize and lead our key brands in the MENA markets. With this partnership, we look forward to further strengthening our current business and be able to expand into new categories and new markets”
COMMENTS